J&J aims to ‘save legs, change lives’ with new peripheral artery disease awareness effortnews2022-04-08T23:58:13+00:00April 8th, 2022|Fierce Pharma|
Fierce Pharma Asia—Legend CSO’s departure; Takeda’s gene therapy deal; Pfizer’s India revampnews2022-04-08T14:13:11+00:00April 8th, 2022|Fierce Pharma|
Vertex CEO Kewalramani nabs more than $15M in 2021 pay, rivaling some male Big Pharma peersnews2022-04-08T14:13:10+00:00April 8th, 2022|Fierce Pharma|
NICE tells Gilead to cut Trodelvy’s price and rejects eczema meds from AbbVie, Pfizer and Leonews2022-04-08T13:30:36+00:00April 8th, 2022|Fierce Pharma|
J&J scores one-two royalty punch against Genmab in blockbuster Darzalex fightnews2022-04-08T12:47:48+00:00April 8th, 2022|Fierce Pharma|
Biogen’s troubled Aduhelm hit with CMS slapdown—now what?news2022-04-08T10:34:36+00:00April 8th, 2022|Fierce Pharma|
AbbVie’s Rinvoq rockets up the pharma TV ad chart in March, but overall spend crashes back to Earthnews2022-04-08T06:54:57+00:00April 8th, 2022|Fierce Pharma|
CMS sticks to its guns, limiting coverage of Biogen’s Aduhelm to clinical trialsnews2022-04-07T22:28:00+00:00April 7th, 2022|Fierce Pharma|
Despite TV ads, most asthma patients don’t recognize new biologic brands, but they’re willing to try them, a survey findsnews2022-04-07T21:06:56+00:00April 7th, 2022|Fierce Pharma|
Eli Lilly, AbbVie positioned for long-term growth, while Bristol Myers Squibb may struggle: analystsnews2022-04-07T18:33:17+00:00April 7th, 2022|Fierce Pharma|
